文献速递肝病

Belapectin(Galectin-3抑制剂)在NASH伴肝硬化及门脉高压患者中的效应

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
PubMed 文献 · Gastroenterology · 2019-12-05

这项2b期随机双盲试验纳入162例NASH伴肝硬化及门脉高压(HVPG≥6 mmHg)患者,每两周静脉输注belapectin 2 mg/kg、8 mg/kg或安慰剂共52周。结果显示belapectin整体未显著降低HVPG或改善纤维化,但在基线无食管静脉曲张亚组(n=81)中,2 mg/kg belapectin与HVPG下降及新发静脉曲张减少相关,且耐受性良好。

要点

  • belapectin 2 mg/kg或8 mg/kg治疗52周整体未显著降低HVPG。
  • belapectin对纤维化、NAFLD活动度评分及肝脏相关结局无显著影响。
  • 基线无食管静脉曲张者用2 mg/kg belapectin与HVPG下降及静脉曲张减少相关。

核心结论

  • 在NASH伴肝硬化及门脉高压患者中,为期1年的belapectin每两周输注安全,但整体未显著降低HVPG或纤维化。
  • 基线无食管静脉曲张亚组中,2 mg/kg belapectin与HVPG降低及新发静脉曲张减少相关。

研究设计与样本

  • 2b期、随机、双盲、多中心(36中心)试验,纳入NASH伴肝硬化及门脉高压(HVPG≥6 mmHg)患者。
  • 患者随机接受每两周静脉输注belapectin 2 mg/kg(n=54)、8 mg/kg(n=54)或安慰剂(n=54),共52周。
  • 主要终点为52周末HVPG较基线的变化(ΔHVPG),次要终点包括肝组织学变化及肝脏相关结局。

主要发现

  • 2 mg/kg组与安慰剂组ΔHVPG分别为-0.28 mmHg与0.10 mmHg,差异无统计学意义(P=1.0)。
  • 8 mg/kg组与安慰剂组ΔHVPG分别为-0.25 mmHg与0.10 mmHg,差异无统计学意义(P=1.0)。
  • belapectin对纤维化或NAFLD活动度评分无显著影响,各组肝脏相关结局无显著差异。
  • 基线无食管静脉曲张亚组(n=81)中,2 mg/kg belapectin与52周HVPG较基线下降相关(P=.02),并减少新发静脉曲张(P=.03)。
  • belapectin 2 mg/kg耐受性良好,未出现安全性信号。

关键数值与推荐

  • 入组标准:NASH伴肝硬化及门脉高压,HVPG≥6 mmHg。
  • 主要终点ΔHVPG:2 mg/kg组-0.28 mmHg vs 安慰剂组0.10 mmHg,P=1.0;8 mg/kg组-0.25 mmHg vs 安慰剂组0.10 mmHg,P=1.0。
  • 亚组(基线无食管静脉曲张,n=81):2 mg/kg belapectin与HVPG下降相关(P=.02),与新发静脉曲张减少相关(P=.03)。

临床怎么用

  • 目前证据不支持belapectin用于NASH伴肝硬化及门脉高压患者降低HVPG或改善纤维化的常规治疗。
  • 基线无食管静脉曲张的患者可能从2 mg/kg belapectin中获益,但需进一步验证。

局限性

  • 亚组分析(基线无食管静脉曲张,n=81)为探索性,样本量有限,结果需谨慎解读。
  • 研究仅评估52周治疗,长期疗效与安全性未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Increased levels of galectin 3 have been associated with nonalcoholic steatohepatitis (NASH) and contribute to toxin-induced liver fibrosis in mice. GR-MD-02 (belapectin) is an inhibitor of galectin 3 that reduces liver fibrosis and portal hypertension in rats and was safe and well tolerated in phase 1 studies. We performed a phase 2b, randomized trial of the safety and efficacy of GR-MD-02 in patients with NASH, cirrhosis, and portal hypertension. METHODS: Patients with NASH, cirrhosis, and portal hypertension (hepatic venous pressure gradient [HVPG] ≥ 6 mm Hg) from 36 centers were randomly assigned, in a double-blind manner, to groups that received biweekly infusions of belapectin 2 mg/kg (n = 54), 8 mg/kg (n = 54), or placebo (n = 54) for 52 weeks. The primary endpoint was change in HVPG (Δ HVPG) at the end of the 52-week period compared with baseline. Secondary endpoints included changes in liver histology and development of liver-related outcomes. RESULTS: We found no significant difference in ΔHVPG between the 2 mg/kg belapectin group and placebo group (-0.28 mm HG vs 0.10 mm HG, P = 1.0) or between the 8 mg/kg belapectin and placebo group (-0.25 mm HG vs 0.10 mm HG, P = 1.0). Belapectin had no significant effect on fibrosis or nonalcoholic fatty liver disease activity score, and liver-related outcomes did not differ significantly among groups. In an analysis of a subgroup of patients without esophageal varices at baseline (n = 81), 2 mg/kg belapectin was associated with a reduction in HVPG at 52 weeks compared with baseline (P = .02) and reduced development of new varices (P = .03). Belapectin (2 mg/kg) was well tolerated and produced no safety signals. CONCLUSIONS: In a phase 2b study of 162 patients with NASH, cirrhosis, and portal hypertension, 1 year of biweekly infusion of belapectin was safe but not associated with significant reduction in HVPG or fibrosis compared with placebo. However, in a subgroup analysis of patients without esophageal varices, 2 mg/kg belapectin did reduce HVPG and development of varices. ClinicalTrials.gov number: NCT02462967.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2019. PMID: 31812510. doi:10.1053/j.gastro.2019.11.296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。